Emergent BioSolutions Reports Financial Results for First Quarter 2020
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Emergent BioSolutions (EBS) PT Raised to $86 at Chardan Capital Markets
May 1, 2020 7:59 AM EDTChardan Capital Markets analyst Keay Nakae raised the price target on Emergent BioSolutions (NYSE: EBS) to $86.00 (from $71.00) while maintaining a Buy rating.
... MoreEmergent BioSolutions (EBS) Reports In-Line Q1 EPS
April 30, 2020 4:39 PM EDTEmergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $192.5 million versus the consensus estimate of $199.47 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
... More